AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27447107 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap-and-water handwashing
Number of subjects: 95
Study 24142232 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01B (40 μg)
Number of subjects: 6
Study 24142232 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01E (10 μg)
Number of subjects: 6
Study 24142232 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01E (20 μg)
Number of subjects: 6
Study 24142232 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS02D (10 μg)
Number of subjects: 6
Study 24142232 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/Saline (40 μg)
Number of subjects: 6
Study 24142232 — intervention group
Group type: COMPARATOR
Intervention: AS01B alone
Number of subjects: 6
Study 22052267 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hyaluronan formulations of different molecular weights (50, 130, 300, 800 and 2000 kDa) applied twice-daily for 60 days
Number of subjects: 76
Study 22052267 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hyaluronan formulations (specifically 130 and 50 kDa)
Number of subjects: 76
Study 22052267 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream applied to the other eye
Number of subjects: 76
Study 19347867 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2-587Arg variant
Number of subjects: 1026
Study 19347867 — intervention group
Group type: EXPERIMENTAL
Intervention: 1759A allele presence
Number of subjects: 1026
Study 16679433 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 482
Study 16679433 — intervention group
Group type: COMPARATOR
Intervention: Delayed start with disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 482
Study 16679433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast radiographic progression during the first year and first 2 years
Number of subjects: 482
Study 16679433 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 482
Study 15531933 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin
Number of subjects: 60
Study 15531933 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin and 25 mg of rofecoxib
Number of subjects: 60
Study 15531933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11125853 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total aggression and attitudinal hostility scores on the BDHI
Number of subjects: 0
Study 11125853 — intervention group
Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 0
Study 9323747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral HIV risk reduction group intervention with advocacy training (7 sessions)
Number of subjects: 104
Study 9323747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral HIV risk reduction group intervention (7 sessions)
Number of subjects: 104
Study 9323747 — intervention group
Group type: COMPARATOR
Intervention: Single AIDS education session
Number of subjects: 104
Study 8400345 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA/PVP formulation (200 mg sachet)
Number of subjects: 26
Study 8400345 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation (500 mg tablet)
Number of subjects: 26
Study 3461726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/butalbital 50 mg/caffeine 40 mg/codeine 30 mg
Number of subjects: 123
Study 3461726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 300 mg/codeine 30 mg
Number of subjects: 123
Study 3461726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 31061718 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Depression Therapy (ADepT) - 15 weekly acute sessions and 5 booster sessions in the following year
Number of subjects: 80
Study 31061718 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) - 20 weekly acute sessions
Number of subjects: 80
Study 29024304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (20 ug/day, intravenous administration diluted with 100 ml normal saline, from 0.5 to 1 hr before to 3 days after operation)
Number of subjects: 480
Study 29024304 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydration therapy only)
Number of subjects: 480
Study 29024304 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 480
Study 27097833 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based progressive resistance training (PRT)
Number of subjects: 49
Study 27097833 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 49
Study 24857532 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training (eight 90-minute sessions)
Number of subjects: 3
Study 24857532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (eight 90-minute sessions)
Number of subjects: 3
Study 24857532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3
Study 22661182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 μg/kg 1 min before administration of fentanyl 2 μg/kg (Group II)
Number of subjects: 400
Study 22661182 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2.5 μg/kg (Group I)
Number of subjects: 400
Study 22661182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 μg/kg 1 min before administration of fentanyl 1.5 μg/kg (Group III)
Number of subjects: 400
Study 22661182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 μg/kg 1 min before administration of fentanyl 1 μg/kg (Group IV)
Number of subjects: 400
Study 20714709 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 18
Study 20714709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17692643 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fenoldopam infusion (0.06 mcg/kg per minute)
Number of subjects: 40
Study 17692643 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 40
Study 15866625 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine or tacrolimus with secondary immunosuppression including mycophenolate match (MMF) or azathioprine
Number of subjects: 20
Study 15866625 — intervention group
Group type: EXPERIMENTAL
Intervention: azathioprine
Number of subjects: 20
Study 15866625 — intervention group
Group type: EXPERIMENTAL
Intervention: delayed graft function
Number of subjects: 20
Study 15866625 — intervention group
Group type: EXPERIMENTAL
Intervention: acute rejection episodes
Number of subjects: 20
Study 15866625 — intervention group
Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 20
Study 12553675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 24
Study 12553675 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 24
Study 9598780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg
Number of subjects: 12
Study 9598780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg
Number of subjects: 12
Study 9598780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg
Number of subjects: 12
Study 9598780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg
Number of subjects: 12
Study 7636773 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative-based intervention
Number of subjects: 80
Study 7636773 — intervention group
Group type: COMPARATOR
Intervention: Traditional, staff-directed intervention
Number of subjects: 80
Study 2651332 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of Tisacid (acid‐neutralizing capacity = 78 mmol)
Number of subjects: 332
Study 2651332 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day of Tisacid (acid‐neutralizing capacity = 156 mmol)
Number of subjects: 332
Study 2651332 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g/day of Tisacid (acid‐neutralizing capacity = 312 mmol)
Number of subjects: 332
Study 2651332 — intervention group
Group type: COMPARATOR
Intervention: 1.0 g/day cimetidine (control)
Number of subjects: 332
Study 138654 — intervention group
Group type: EXPERIMENTAL
Intervention: Terracortril ointment or cream
Number of subjects: 85
Study 30545717 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine as weekly chemoprophylaxis
Number of subjects: 0
Study 30545717 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine as intermittent treatment
Number of subjects: 0
Study 30545717 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28624580 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (pantoprazole 40 mg/day)
Number of subjects: 30
Study 24732671 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 200 μg
Number of subjects: 183
Study 24732671 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 100 μg
Number of subjects: 183
Study 24732671 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 183
Study 24021303 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ‐50300 smallpox vaccine administered with a bifurcated needle over the deltoid muscle.
Number of subjects: 145
Study 21721072 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral intervention
Number of subjects: 90
Study 21721072 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 90
Study 21721072 — intervention group
Group type: COMPARATOR
Intervention: Weekly assessment
Number of subjects: 90
Study 19555036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5.0 mg/day)
Number of subjects: 92
Study 19555036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradin (mean dose 7.5 mg)
Number of subjects: 92
Study 19555036 — intervention group
Group type: COMPARATOR
Intervention: Basic combined therapy (ACE inhibitors, diuretics, aspirin, statins, on demand nitrates)
Number of subjects: 92
Study 16290998 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 80
Study 16290998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12127368 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase Plane (PP) ECG analysis
Number of subjects: 18
Study 12127368 — intervention group
Group type: COMPARATOR
Intervention: Standard ECG analysis
Number of subjects: 18
Study 10187933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray (group II)
Number of subjects: 75
Study 10187933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infiltrative anesthesia (group III)
Number of subjects: 75
Study 10187933 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (group I)
Number of subjects: 75
Study 8800725 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (group II, n = 100)
Number of subjects: 195
Study 8800725 — intervention group
Group type: COMPARATOR
Intervention: Stanford solution (group I, n = 95)
Number of subjects: 195
Study 2146389 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct trocar insertion
Number of subjects: 0
Study 2146389 — intervention group
Group type: COMPARATOR
Intervention: Verres needle use
Number of subjects: 0
Study 313148 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 74
Study 313148 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 74
Study 313148 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from medical to surgical therapy
Number of subjects: 74
Study 313148 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 74
Study 313148 — intervention group
Group type: COMPARATOR
Intervention: Predictors of total inpatient cost
Number of subjects: 74
Study 31324199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanjin tablets plus levofloxacin tablets placebo
Number of subjects: 252
Study 31324199 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin tablets plus Sanjin tablets placebo
Number of subjects: 252
Study 31324199 — intervention group
Group type: COMPARATOR
Intervention: Sanjin tablets plus levofloxacin tablets
Number of subjects: 252
Study 28467145 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP‐I Plan intervention (includes emotional support and systems navigation)
Number of subjects: 74
Study 28467145 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 74
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneas from donors younger than 66 years
Number of subjects: 1090
Study 25322173 — intervention group
Group type: COMPARATOR
Intervention: Corneas from donors 66 years or older
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a history of glaucoma before penetrating keratoplasty
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 70 years or older
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: African American recipients
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients with a history of smoking
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower endothelial cell density (ECD) at 6 months
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher corneal thickness (CT) at 6 months
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ECD at 1 year
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CT at 1 year
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ECD at 5 years
Number of subjects: 1090
Study 25322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CT at 5 years
Number of subjects: 1090
Study 23358295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and Physical Activity (NPA) intervention
Number of subjects: 673
Study 23358295 — intervention group
Group type: COMPARATOR
Intervention: Cancer Education (CE)
Number of subjects: 673
Study 21640042 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5mg BID
Number of subjects: 61
Study 21640042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 19363703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT)
Number of subjects: 131
Study 19363703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus and reduced diphtheria (Td)
Number of subjects: 131
Study 16848997 — intervention group
Group type: EXPERIMENTAL
Intervention: SBC (selective brain cooling) group
Number of subjects: 96
Study 16848997 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH (mild systemic hypothermia) group
Number of subjects: 96
Study 16848997 — intervention group
Group type: COMPARATOR
Intervention: Control (normothermia) group
Number of subjects: 96
Study 16048569 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume paracentesis (LVP) with intravenous albumin
Number of subjects: 42
Study 16048569 — intervention group
Group type: COMPARATOR
Intervention: Diuretics with intravenous albumin
Number of subjects: 42
Study 11930101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (1.2 mg/kg)
Number of subjects: 97
Study 11930101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 10594421 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20
Study 10594421 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 20
Study 8597003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 200 mg 4-hourly
Number of subjects: 191
Study 8597003 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 125 mg 12-hourly
Number of subjects: 191
Study 2132290 — intervention group
Group type: EXPERIMENTAL
Intervention: morniflumate (700 mg tablet twice a day) + amoxicillin (1 g tablet twice a day)
Number of subjects: 60
Study 2132290 — intervention group
Group type: EXPERIMENTAL
Intervention: feprazone (200 mg tablet twice a day) + amoxicillin (1 g tablet twice a day)
Number of subjects: 60
Study 2132290 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin (1 g tablet twice a day)
Number of subjects: 60
Study 500516 — intervention group
Group type: COMPARATOR
Intervention: GENT alone at a dose of 1.5 mg/kg/8 hourly
Number of subjects: 67
Study 500516 — intervention group
Group type: EXPERIMENTAL
Intervention: GENT + CTIN at a dose of 2 g or 3 g 8 hourly by i.v. bolus
Number of subjects: 67
Study 31703674 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout assessment using Maslach Burnout Inventory-Human Services Survey (MBI-HSS)
Number of subjects: 151
Study 31703674 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Exhaustion (EE)
Number of subjects: 151
Study 31703674 — intervention group
Group type: EXPERIMENTAL
Intervention: Depersonalization (DP)
Number of subjects: 151
Study 31703674 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Accomplishment (PA)
Number of subjects: 151
Study 31703674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfaction with practice lecturer
Number of subjects: 151
Study 31703674 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate social support
Number of subjects: 151
Study 31703674 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with education
Number of subjects: 151
Study 28086181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 82
Study 28086181 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 82
Study 28086181 — intervention group
Group type: COMPARATOR
Intervention: Brief treatment
Number of subjects: 82
Study 25431429 — intervention group
Group type: EXPERIMENTAL
Intervention: Social recovery cognitive-behavioural therapy (SRCBT)
Number of subjects: 0
Study 25431429 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23595562 — intervention group
Group type: COMPARATOR
Intervention: Bazedoxifene (BZA)
Number of subjects: 0
Study 23595562 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (RLX) 60 mg
Number of subjects: 0
Study 21550357 — intervention group
Group type: EXPERIMENTAL
Intervention: Food anticipation (14 subjects)
Number of subjects: 29
Study 21550357 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding anticipated food (14 subjects)
Number of subjects: 29
Study 21550357 — intervention group
Group type: COMPARATOR
Intervention: Fasted controls (15 subjects)
Number of subjects: 29
Study 19736154 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting biodegradable polymer stents (BES)
Number of subjects: 153
Study 19736154 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting permanent polymer stents (SES)
Number of subjects: 153
Study 17845921 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) for 4 weeks
Number of subjects: 35
Study 17845921 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/day) for 4 weeks
Number of subjects: 35
Study 14743356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyskinesias
Number of subjects: 301
Study 14743356 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger subjects
Number of subjects: 301
Study 14743356 — intervention group
Group type: COMPARATOR
Intervention: Motor fluctuations
Number of subjects: 301
Study 14743356 — intervention group
Group type: COMPARATOR
Intervention: Treatment regimen
Number of subjects: 301
Study 11770416 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention for COPD and chronic cor-pulmonale
Number of subjects: 3739
Study 11770416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3739
Study 9670269 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hyperthermic liver perfusion (IHLP) with anticancer agents
Number of subjects: 10
Study 7920751 — intervention group
Group type: EXPERIMENTAL
Intervention: Decapeptyl (D‐Trp6‐LHRH) depot 3.2 mg for 3‐6 months + conservative myomectomy
Number of subjects: 23
Study 7920751 — intervention group
Group type: COMPARATOR
Intervention: Decapeptyl (D‐Trp6‐LHRH) depot 3.2 mg for 3‐6 months without myomectomy
Number of subjects: 23
Study 2967712 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen
Number of subjects: 0
Study 2967712 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (control)
Number of subjects: 0
Study 31525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of concentrated water-in-oil emulsions
Number of subjects: 0
Study 31525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of concentrated water-in-oil emulsions with isopropyl myristate
Number of subjects: 0
Study 31525444 — intervention group
Group type: COMPARATOR
Intervention: Topical application of concentrated water-in-oil emulsions with liquid paraffin
Number of subjects: 0
Study 29098783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS), 20 g/day
Number of subjects: 869
Study 29098783 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN)
Number of subjects: 869
Study 29098783 — intervention group
Group type: COMPARATOR
Intervention: Control iron/folic acid (IFA) tablet
Number of subjects: 869
Study 29098783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for IFA control group post-delivery)
Number of subjects: 869
Study 26976423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Irinotecan (BEV+IRI)
Number of subjects: 182
Study 26976423 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 182
Study 26976423 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) measures (QLQ-C30 and QLQ-BN20)
Number of subjects: 182
Study 24274259 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily for 3 months
Number of subjects: 38
Study 24274259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21954883 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelsemium 15CH
Number of subjects: 180
Study 21954883 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelsemium 5CH
Number of subjects: 180